|
Market Closed -
Other stock markets
|
After hours 19:58:16 | |||
| 66.75 EUR | +0.45% |
|
67.68 | +1.39% |
| 02:59pm | Number of Pharmacies in Germany Drops to Lowest Level in Nearly 50 Years | DP |
| 09:30am | REDCARE PHARMACY : Jefferies reiterates its Buy rating | ZD |
| Capitalization | 1.35B 1.57B 1.26B 1.17B 2.19B 142B 2.36B 14.49B 5.69B 67.89B 5.9B 5.78B 250B | P/E ratio 2025 * |
-58.6x | P/E ratio 2026 * | 284x |
|---|---|---|---|---|---|
| Enterprise value | 1.5B 1.74B 1.4B 1.3B 2.42B 157B 2.61B 16.04B 6.3B 75.15B 6.53B 6.4B 277B | EV / Sales 2025 * |
0.51x | EV / Sales 2026 * | 0.43x |
| Free-Float |
98.85% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Redcare Pharmacy NV
| 1 day | +1.84% | ||
| 1 week | -3.33% | ||
| Current month | +2.53% | ||
| 1 month | +6.54% | ||
| 3 months | -23.80% | ||
| 6 months | -27.60% | ||
| Current year | +2.53% |
| 1 week | 64.6 |  | 73.25 |
| 1 month | 60.2 | | 73.25 |
| Current year | 64.6 | | 73.25 |
| 1 year | 59.45 | | 144.4 |
| 3 years | 59.45 | | 171.4 |
| 5 years | 36.51 | | 249 |
| 10 years | 24 | | 249 |
| Manager | Title | Age | Since |
|---|---|---|---|
Olaf Heinrich
CEO | Chief Executive Officer | 56 | 31/07/2023 |
Hendrik Krampe
DFI | Director of Finance/CFO | - | 30/11/2025 |
Lode Fastré
CTO | Chief Tech/Sci/R&D Officer | - | 16/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Jérôme Cochet
BRD | Director/Board Member | 48 | 31/08/2016 |
Björn H. Söder
CHM | Chairman | 54 | 20/04/2021 |
| Director/Board Member | 55 | 13/04/2022 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.45% | -3.33% | -40.88% | +4.33% | 1.58B | |
| +0.52% | +15.81% | +144.65% | +0.82% | 27.6B | |
| +2.83% | +22.93% | +101.23% | -10.66% | 13.19B | |
| -1.28% | -3.48% | +20.19% | +23.56% | 6.68B | |
| +2.28% | +3.99% | -7.49% | +23.05% | 4.98B | |
| +1.91% | +2.51% | -8.53% | -38.60% | 3.83B | |
| -0.21% | +1.57% | -20.95% | -47.33% | 3.26B | |
| -0.05% | +4.34% | +34.18% | -48.22% | 3.03B | |
| +1.30% | 0.00% | -9.17% | +68.73% | 2.83B | |
| -1.84% | -1.15% | +47.03% | - | 2B | |
| Average | +0.73% | +3.79% | +26.03% | -2.70% | 6.9B | |
| Weighted average by Cap. | +0.93% | +10.07% | +78.75% | -1.37% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 2.95B 3.44B 2.75B 2.56B 4.78B 310B 5.15B 31.67B 12.44B 148B 12.89B 12.63B 547B | 3.49B 4.06B 3.25B 3.02B 5.64B 366B 6.08B 37.36B 14.68B 175B 15.21B 14.9B 646B |
| Net income | -18.81M -21.89M -17.54M -16.3M -30.41M -1.98B -32.79M -202M -79.23M -945M -82.09M -80.41M -3.48B | 3.86M 4.49M 3.6M 3.34M 6.24M 406M 6.73M 41.38M 16.26M 194M 16.85M 16.5M 715M |
| Net Debt | 144M 168M 135M 125M 234M 15.19B 252M 1.55B 609M 7.26B 631M 618M 26.77B | 143M 167M 133M 124M 231M 15.04B 249M 1.53B 603M 7.19B 625M 612M 26.51B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/01/26 | 66.75 € | +0.45% | 156,381 |
| 12/01/26 | 66.45 € | +1.14% | 148,368 |
| 09/01/26 | 65.70 € | -0.45% | 81,329 |
| 08/01/26 | 66.00 € | -1.35% | 140,365 |
| 07/01/26 | 66.90 € | -6.43% | 446,260 |
Delayed Quote Xetra, January 13, 2026 at 04:35 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- RDC Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition